<!DOCTYPE HTML>

<!--

	Solid State by HTML5 UP

	html5up.net | @n33co

	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)

-->

<html>

	<head>

                <title>Cognitive symptoms</title>

		<meta charset="utf-8" />

		<meta name="viewport" content="width=device-width, initial-scale=1" />

		<!--[if lte IE 8]><script src="assets/js/ie/html5shiv.js"></script><![endif]-->

		<link rel="stylesheet" href="assets/css/main.css" />

		<!--[if lte IE 9]><link rel="stylesheet" href="assets/css/ie9.css" /><![endif]-->

		<!--[if lte IE 8]><link rel="stylesheet" href="assets/css/ie8.css" /><![endif]-->

	</head>

	<body>



		<!-- Page Wrapper -->

			<div id="page-wrapper">
				<!-- Header -->
					<header id="header">
						<h1><a href="index.html">Introduction</a></h1>
						<nav>
							<a href="#menu">Menu</a>
						</nav>
					</header>

				<!-- Menu -->
					<nav id="menu">
						<div class="inner">
							<h2>Menu</h2>
							<ul class="links">
								<li><a href="index.html">Home</a></li>

                        <li><a href="autonomic.html">Autonomic features</a></li>
                        
                        <li><a href="cognition.html">Cognitive features</a></li>
                        
                        <li><a href="sleep.html">Sleep</a></li>
                        
                        <li><a href="others.html" >Other symptoms</a></li>
                        
							</ul>
							<a href="#" class="close">Close</a>
						</div>
					</nav>

				<!-- Wrapper -->

					<section id="wrapper">

						<header>

							<div class="inner">

								<h2>Cognitive symptoms</h2>
								<p>
								  Although Parkinson's disease is not a dementia, 80% of patients will have detectable cognitive impairment after 10 years.
							   </p>
								  
		  						</header>
		  						<p>Cognitive changes in Parkinson's disease takes two forms, early changes affecting the frontal lobes and later dementia affecting posterior brain regions. The related condition Lewy Body Dementia is beyond the scope of this eLearning package.
								</p>
								
								<h3>Frontal dysexecutive syndrome</h3>
								<p>
								  Changes in the frontal lobes in Parkinson's disease are subtle yet common. They are not as prominent as in other disorders (eg Frontotemporal dementia). The most prominent changes are in executive function, which involves planning and rule learning.
								</p>
								
								<p>
								  One simple test of executive funtion is the Trails Test, which is part of the <a href="http://www.mocatest.org/" target="MOCA">Montreal Cognitive Assessment</a>.
								</p>
								<figure>
									<img src="images/trails.png" alt="TrailsB">
									<figcaption>This is a practice example of the trails test. The subject must complete the dot-to-dot by alternating letters and numbers, ie A-1-B-2-C-3 etc. To accurately complete the test requires executive functions of planning, rule learning and set shifting (ie numbers to letters).</figcaption>
								</figure>								
								
								<h3>Parkinson's disease dementia</h3>
								<p>
								  Changes in posterior brain regions may herald the onset of Parkinson's disease dementia and usually occur late in the disease process. Not everybody with Parkinson's disease will develop a dementia, but there are tests that can help predict who will do so.
								</p>
								
								<figure>
								  <img src="images/InterlockingPentagons.png" alt="Interlocking pentagons">
								  <figcaption>Copying this diagram tests constructional apraxia, a parietal lobe function.</figcaption>
								</figure>
								
								<p>
								  Difficulty copying these interlocking pentagons can predict later cognitive decline. Other risk factors for developing dementia include poor verbal fluency (generating words beginning with a given letter over 1 minute), non-tremor dominant presentation, age over 72 and Unified Parkinson's Disease Rating Scale (UPDRS) motor score &geq;25.
								</p>
								
								<p>There is a genetic association between the H1/H1 MAPT genotype (the gene encoding the tau protein) and the <a href="http://brain.oxfordjournals.org/content/132/11/2958.long">development of Parkinson's disease dementia with an odds ratio of 12.1.</a></p>
								
								<h3>Medications and cognition</h3>
								<p>
								  It is important to note that dopaminergic medication may make some aspects of cognition worse. Hallucinations and paranoia may be exacerbated by the effect of dopamine D2 receptors in mesolimbic pathways. Frontal dysexecutive cognition may also be made worse by 'overloading' dopaminergic systems in the prefrontal cortex.
								</p>
								
								<p>Cholinesterase inhibitors play a role in treating hallucinations, attentional and memory symptoms in Parkinson's disease.</p>


		<!-- Scripts -->

			<script src="assets/js/skel.min.js"></script>

			<script src="assets/js/jquery.min.js"></script>

			<script src="assets/js/jquery.scrollex.min.js"></script>

			<script src="assets/js/util.js"></script>

			<!--[if lte IE 8]><script src="assets/js/ie/respond.min.js"></script><![endif]-->

			<script src="assets/js/main.js"></script>



	</body>
</html>

